| Summary: | The pathogenesis of AD has not been fully elucidated, and it is currently recognized that it is related to genetic and environmental factors, skin barrier dysfunction and immune dysregulation dominated by type 2 inflammation. In recent years, with the in-depth study of intestinal microbiota, microbe therapy may make up for the shortage of topical glucocorticoids and other treatments. This article focuses on the relationship of the changes in microecology with the pathogenesis of AD, elaborates the important role of intestinal microbiota, cutaneous microbiota and their metabolites in AD, and reviews the research progress in microbe therapy, so as to provide new enlightenment for the treatment of AD.
|
|---|